Sepsis, a condition causing life-threatening organ dysfunction due to uncontrolled infections, has emerged as a major global health challenge, claiming millions of lives annually. Despite rigorous treatment protocols, current approaches primarily focus on containment and organ support, leaving a significant gap in managing the underlying inflammatory response. Efferon, an Austrian company founded in 2016, is striving to bridge this gap by developing blood purification devices designed to minimize sepsis-associated mortality. Amidst the urgency fueled by the staggering statistics, Efferon’s technology potentially changes the dynamics in critical care environments globally.
ETH
SOL
BSC
ROBINHOOD
USDT
AAPL
The incidence and management of sepsis have evolved, and initiatives to tackle this condition have gained momentum over recent years. Historically, technologies to address sepsis’s complex nature focused on solutions either targeting bacterial components like endotoxins or managing cytokine storms. Nevertheless, challenges remained in deploying comprehensive therapies that address both dimensions concurrently. These developments contrast with Efferon’s contemporary strategy of tackling inflammation and toxin presence simultaneously, marking a shift in innovative approaches towards holistic sepsis treatment.
What Sets Efferon Apart?
At the center of Efferon’s strategy is the development of blood purification technology that targets both bacterial toxins, such as lipopolysaccharide (LPS), and inflammatory mediators like cytokines. This dual-action process helps stabilize patients and enhance the effectiveness of conventional treatments. Blood drawn from patients is passed through Efferon’s filtration device, capturing harmful components before being reinfused. This dual-targeting approach, according to the company’s CEO Dima Romashin, helps manage the dual threat of sepsis more comprehensively.
How are Pediatric Cases Addressed?
Efferon’s developments extend beyond adult ICUs into neonatal and pediatric care, where specific adaptations in devices address smaller blood volumes and fragile conditions. The pediatric-focused Efferon NEO product, certified in 2026 for EU use, highlights the company’s dedication to addressing sepsis across all ages. Romashin underscores the importance of designing devices specifically for children, emphasizing unique challenges such as premature infants with underdeveloped organs. He remarks on the intricacies of saving young lives, illustrated by the successful treatment of infants as small as 1.2 kilograms.
In the field of blood purification, various businesses contribute innovative solutions to manage sepsis’s complexities. Unlike some competitors that solely target LPS or cytokines, Efferon aims to address both simultaneously, thereby “selling time” for patients to benefit from a full spectrum of available treatments, highlighted as key in their approach.
“We’re helping to interrupt the inflammatory process so that during those first critical days, the patient can be stabilised and the other therapies have time to work.”
Efferon’s clinical trials encompass a range of studies assessing the efficacy of their technology in managing sepsis, showing reduced recovery time from septic shock and decreased dependency on support systems. Importantly, a significant reduction in mortality is noted in both adult and pediatric studies, establishing a promising precedent for this approach.
Aftercare for sepsis survivors is an area receiving increased focus due to potential long-term health repercussions. Efferon’s engagement in post-sepsis patient monitoring highlights valuable insights into recovery trajectories, advocating for continued attention to patient outcomes beyond immediate crisis management. Romashin points out the sustained impact on patients’ immune systems, emphasizing that post-crisis care is critical for lasting recovery.
“In children, we were also able to demonstrate a statistically significant impact on 28-day mortality. We saw around a fourfold reduction in mortality over that period.”
Looking forward, Efferon expands its footprint into new markets, with pathways targeting U.S. and Chinese regulatory approval. The company is also exploring applications in inflammatory diseases outside intensive care, supporting treatment for conditions such as Long Covid and persistent inflammation, with potential 2027 market availability.
